Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) started the day on Thursday, with a price increase of 3.56% at $445.12, before settling in for the price of $429.8 at the close. Taking a more long-term approach, ALNY posted a 52-week range of $205.87-$495.55.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 23.11%. Meanwhile, its Annual Earning per share during the time was 23.11%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 212.31%. This publicly-traded company’s shares outstanding now amounts to $131.79 million, simultaneously with a float of $129.75 million. The organization now has a market capitalization sitting at $58.81 billion. At the time of writing, stock’s 50-day Moving Average stood at $456.02, while the 200-day Moving Average is $351.58.
Alnylam Pharmaceuticals Inc (ALNY) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Alnylam Pharmaceuticals Inc’s current insider ownership accounts for 1.79%, in contrast to 99.34% institutional ownership. According to the most recent insider trade that took place on Nov 17 ’25, this organization’s CSO & EVP, Head of Research sold 12,128 shares at the rate of 452.18, making the entire transaction reach 5,483,990 in total value, affecting insider ownership by 21,264.
Alnylam Pharmaceuticals Inc (ALNY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.09 per share during the current fiscal year. Alnylam Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 212.31% and is forecasted to reach 7.53 in the upcoming year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Let’s observe the current performance indicators for Alnylam Pharmaceuticals Inc (ALNY). It’s Quick Ratio in the last reported quarter now stands at 2.49. Alongside those numbers, its PE Ratio stands at $1851.58, and its Beta score is 0.31. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 18.32. Similarly, its price to free cash flow for trailing twelve months is now 265.66.
In the same vein, ALNY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.24, a figure that is expected to reach 1.24 in the next quarter, and analysts are predicting that it will be 7.53 at the market close of one year from today.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
If we take a close look at the recent performances of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), its last 5-days Average volume was 1.15 million that shows progress from its year to date volume of 1.0 million. During the previous 9 days, stock’s Stochastic %D was recorded 32.95% While, its Average True Range was 48.19.
Raw Stochastic average of Alnylam Pharmaceuticals Inc (ALNY) in the period of the previous 100 days is set at 72.88%, which indicates a major rise in contrast to 50.85% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 14.32 that was higher than 13.61 volatility it exhibited in the past 100-days period.
